Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $26.38
Previous CloseN/A
Volume72.82K
Average Volume (3M)128.34K
Market Cap
$18.41M
Enterprise Value$80.40M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Apr 07, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding8,253,741
10 Day Avg. Volume86,690
30 Day Avg. Volume128,340
Standard Deviation0.35
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.83
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-62.15
Enterprise Value/Ebitda-5.97
Forecast
1Y Price Target
$8.67Price Target Upside273.71% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
CervoMed News
PremiumCompany Announcements
CervoMed Updates on Neflamapimod Trials for Dementia
---
Bulls Say, Bears Say
Bulls Say
Financial PositionCervoMed ended with $46.7M in cash and cash equivalents, which should provide the company with some strategic optionality regardless of the ultimate fate of neflamapimod.
Safety ProfileNeflamapimod displayed a favorable safety and tolerability profile that is consistent with prior clinical studies, with no new safety signal identified.
Shareholder ValueThere may be opportunities to rebuild shareholder value despite the recent setback.
Bears Say
Clinical Trial ResultsThe trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints.
Plasma ConcentrationsNeflamapimod plasma concentrations below target represent a meaningful headwind for demonstrating proof-of-concept.
Stock DowngradeCRVO shares are downgraded to Underweight as there are better opportunities elsewhere.
---
Ownership Overview
48.25% Insiders
7.15% Mutual Funds
1.97% Other Institutional Investors
35.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.80 and its highest was $26.38 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $18.41M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Apr 07, 2025 which is in 45 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 12, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.138.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.67.
How many shares outstanding does CervoMed have?
CervoMed has 8,253,741 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went down -2.554%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
---
Company Description
CervoMed
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
---
CRVO Stock 12 Month Forecast
Average Price Target
$8.67
▲(273.71% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Cassava Sciences
―
Anavex Life Sciences
―
Axsome Therapeutics
―
Best Analysts Covering CRVO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-75.01%
reiterated a buy rating 2 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -75.01% per trade.
---